ong-term neuropsychological outcome in pediatric anti-NMDAR encephalitis

• Conditions: hersenontsteking; NMDA receptor encefalitis; 10003816; 10014623; 10009841

• Registration Number: NL-OMON42623
• Lead Sponsor: eurologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

- Cross-sectional part: patients who have had anti-NMDA receptor encephalitis before January 2015, who were age 18 or younger at disease onset and currently age 4 or older.
- Prospective parts: patients who have had anti-NMDA receptor encephalitis after January 2015, who were age 3.5 to 18 at disease onset
- Patient was diagnosed in Dutch tertiary pediatric hospitals, or antibody testing had been performed in our center.
- Patient speaks Dutch or English.

Exclusion Criteria

- Age over 18 years at disease onset, or current age younger than 4
- Patient or legal representative is withholding informed consent
- Patient or legal representative objects after initial informed consent (see paragraph 8.4)

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Identification of clusters of impairment in cognition and behavior after<br /><br>pediatric anti-NMDAR encephalitis </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Identification of risk factors affecting functional outcome<br /><br>- Analyzing progression or remission over time<br /><br>- Analyzing the phenomenom of 'growing into deficit'</p><br>